Takeda presents new exploratory analysis showing patients treated with livtencity™ (maribavir) had reductions in hospitalization rates and length of hospital stay

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) (“takeda”) today announced that it will present four company-sponsored abstracts at the tandem transplantation & cellular therapy meetings in salt lake city, utah, and the 32nd european congress of clinical microbiology and infectious diseases (eccmid) in lisbon, portugal between april 23 and 26, 2022. the exploratory data presented at both meetings provide an opportunity to share important new analyses of livtenci
TAK Ratings Summary
TAK Quant Ranking